Epidermal growth factor receptor (EGFR) overexpression and prognostic value in head and neck squamous cell cancer is the basis for targeting by anti-EGFR antibodies, which increase the efficacy of radiotherapy. In order to evaluate the best therapeutic schedule, the effects of cetuximab (C225) on Hep-2 cell proliferation, alone and in combination with cisplatin, were studied.
Bussu, F., Pozzoli, G., Giglia, V., Rizzo, D., Limongelli, A., De Corso, E., Graziani, C., Paludetti, G., Navarra, P., Almadori, G., Effects of the administration of epidermal growth factor receptor specific inhibitor cetuximab, alone and in combination with cisplatin, on proliferation and apoptosis of Hep-2 laryngeal cancer cells, <<JOURNAL OF LARYNGOLOGY AND OTOLOGY>>, 2014; 128 (10): 902-908. [doi:10.1017/S002221511400190X] [http://hdl.handle.net/10807/60258]
Effects of the administration of epidermal growth factor receptor specific inhibitor cetuximab, alone and in combination with cisplatin, on proliferation and apoptosis of Hep-2 laryngeal cancer cells
Bussu, Francesco;Pozzoli, Giacomo;Giglia, Veronica;Rizzo, Davide;Limongelli, Attilio;De Corso, Eugenio;Graziani, Cristina;Paludetti, Gaetano;Navarra, Pierluigi;Almadori, Giovanni
2014
Abstract
Epidermal growth factor receptor (EGFR) overexpression and prognostic value in head and neck squamous cell cancer is the basis for targeting by anti-EGFR antibodies, which increase the efficacy of radiotherapy. In order to evaluate the best therapeutic schedule, the effects of cetuximab (C225) on Hep-2 cell proliferation, alone and in combination with cisplatin, were studied.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
